БЕРКЕНБЛИТ Анна (US),БИНЛИШ Флоренс (FR),ГОСС Пол (US)
申请号：
RU2011139363/14
公开号：
RU2011139363A
申请日:
2010.03.24
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A treatment regimen for cancer with overexpression / amplification of HER-2 / neu, including treatment with neratinib in patients with cancer with overexpression / amplification of HER-2 / neu after completion of treatment with trastuzumab. 2. The regimen according to claim 1, wherein the course of treatment with neratinib includes the treatment of patients with neratinib cancer for at least one month. The scheme according to claim 1, where the course of treatment with neratinib has a duration in the range from 8 months to 5 years. The regimen of claim 2, wherein cancer patients are treated with neratinib for at least about 12 months. The regimen of claim 1, wherein treatment with neratinib is started after about 2 weeks to about one year after completion of surgical treatment and standard adjuvant therapy. The regimen of claim 1, wherein neratinib is administered orally. The regimen of claim 6, wherein the neratinib is administered in tablet form. The regimen of claim 1, wherein neratinib is administered daily. The regimen according to claim 1, wherein neratinib is administered at a dose of 120 mg to 300 mg per day. The regimen of claim 9, wherein neratinib is administered at a dose of 240 mg. A method for increasing survival without signs of invasive disease (IDFS) or survival without signs of disease (DFS) with ductal carcinoma in situ (DCIS) and / or increasing overall survival, time to systemic relapse and survival without signs of systemic relapse in a patient, comprising administering neratinib to said patient after treatment with trastuzumab. 12. The method of claim 11, wherein the patient has received at least three treatment cycles with trastuzumab. The method of claim 12, wherein the patient received twelve cycles of trastuzumab treatment. The method of claim 11, wherein the patient received standard adjuvant therapy consisting of trastuzumab and one or more1. Схема лечения рака со сверхэкспрессией/амплификацией HER-2/neu, включающая проведение лечения
